Trial reportTranslational stroke research2026
Comprehensive Evaluation of Predictive Significance of FABP4 for Long-term Clinical Outcomes After Ischemic Stroke.
Trial report in Translational stroke research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Fatty acid-binding protein 4 (FABP4) has been reported to be involved in cerebral ischemia injury by modulating neurological function and inflammatory responses. This study aimed to investigate the association between plasma FABP4 levels and long-term, comprehensive clinical outcomes after acute ischemic stroke. Plasma FABP4 levels were measured in 3352 patients with acute ischemic stroke from the Chinese Acute Ischemic Stroke Antihypertensive Trial. Primary outcome was the composite of death and major disability (modified Rankin Scale score ≥ 3); secondary outcomes included major disability, all-cause mortality, stroke-specific mortality, and cardiovascular events. After 24-month follow-up, 790 patients experienced primary outcome, including 502 major disability and 288 all-cause mortality. Compared with the lowest tertile, the highest tertile of FABP4 was associated with primary outcome (odds ratio [OR] 1.60, 95% confidence interval [CI] 1.27-2.00), major disability (OR 1.40, 95% CI 1.09-1.82), all-cause mortality (hazard ratio [HR] 1.58, 95% CI 1.15-2.17), stroke-specific mortality (HR 1.68, 95% CI 1.17-2.40), and cardiovascular events (HR 1.35, 95% CI 1.02-1.80). Adding FABP4 to the basic model with conventional risk factors significantly improved risk reclassification for primary outcome (net reclassification improvement: 24.95%; integrated discrimination index: 0.75%). FABP4 was among the top five important predictors for primary outcome, ranking higher than N-terminal pro-brain natriuretic peptide and other biomarkers. Elevated plasma FABP4 levels were associated with increased risks of a variety of adverse outcomes after ischemic stroke at 24 months, suggesting that FABP4 could serve as a promising biomarker to improve risk stratification for long-term prognosis in ischemic stroke.
Indexed as
Identifiers
41790304What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.